Clinical Trial Update: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on Ga-68 PSMA-11 for detecting biochemical recurrence of prostate cancer in Chinese patients; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biochemical Recurrence of Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer | Phase 3 | Status: RECRUITING